FeNO testing

Innovation Type: Diagnostic Device

Innovation Origin: AHSN National Programme, Accelerated Access Collaborative (AAC)

A Fractional exhaled Nitric Oxide (FeNO) test is a way of measuring the amount of nitric oxide in an exhaled breath. This test can help with the diagnosis of asthma by showing the level of inflammation in the lungs.

The NHS Accelerated Access Collaborative (AAC) is the umbrella organisation for UK health innovation. It supports the NHS to quickly adopt clinically and cost-effective innovations, and to ensure patients get access to the best new treatments and technologies. It does this through the Rapid Uptake Products (RUP) programme. This programme delivers bespoke support initiatives to increase system wide uptake and spread.

The aim of the FeNO Rapid Uptake Product (RUP) programme is to:

• Improve patient care and outcomes by more effectively diagnosing patients with suspected asthma 
• Increase widespread patient and clinician access to FeNO testing across primary care

For more information, please visit: https://wessexahsn.org.uk/programmes/56/feno-fractional-exhaled-nitric-oxide-for-the-diagnosis-and-management-of-asthma